Bio-Rad introduces SARS-CoV-2 serology assays

The coupled beads can be used to measure antibodies in any species, making the assay useful for both preclinical and clinical trials, the company says

Bio-Rad Laboratories has announced the launch of the Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel, for research use only (RUO).

The qualitative multiplex immunoassay kit detects IgG antibodies against four SARS-CoV-2 antigens, designed to enable vaccine developers to determine therapeutic efficacy from development through all clinical phases.

The panel is a ready-to-use 96-well kit containing premixed magnetic capture beads, an IgG-specific detection antibody, positive and negative controls, and buffers that produce results for four anti–SARS-Cov-2 antibodies using 5 microlitres of sample. The offering includes singleplex assay reagents, enabling measurement of specific viral antigens of interest, and generates actionable data in a single experiment. The kit is compatible with RUO Bio-Rad platforms, including the Bio-Plex 200 and Bio-Plex 3D Multiplex Immunoassay Systems, as well as all other RUO xMAP platforms.

In addition, the kit enables public health researchers to perform seroprevalence studies. This could help to identify the number of persons in a population who have been exposed to SARS-CoV-2 based on serology specimens, capturing individuals who have not received a COVID-19 diagnosis due to experiencing only mild symptoms or being asymptomatic.

“Detecting levels of antibodies against SARS-CoV-2 provides useful information about natural exposure rates in a population or about vaccine immunogenicity,” said Candice Cox, Bio-Rad Immunoassays Marketing Manager, Life Science Group. “We are pleased to be able to offer this new immunoassay kit to researchers working in vaccine development and related fields.”

Companies